Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,inventory,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,totalCashFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,marketState,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,ICLR,945835000.0,52860700,,,113270000,,97122000,86635000,232554000,128514000,128514000,,-2727000,,,,16148000,858198000,729684000,625644000,-15244000,,97122000,97122000,60598000.0,623409000.0,1532405000.0,1934171000.0,1008346000.0,3466576000.0,4585000.0,1360017000.0,51397000.0,927738000.0,-53840000.0,45916000.0,942455000.0,1080234000.0,12552000.0,-53840000.0,240383000.0,2169067000.0,22874000.0,1729000.0,1137610000.0,348592000.0,48103000.0,,-599000.0,-52990000.0,-9303000.0,-31590000.0,5000.0,102150000.0,-467000.0,111920000.0,24520000.0,63811000.0,-5000.0,4256000.0,-8704000.0,,1088833000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,258.22,1630526403,2.449997,255.32,258.62,254.55,367713,43.963196,0.20518926,13649689600,27.067085,7.056734,15,America/New_York,EDT,-14400000,False,False,USD,2,ICON plc,NMS,9.13,28.282585,36.592,236.17372,22.04628,0.09334773,214.2568,0,finmb_397809,NasdaqGS,ICON Public Limited Company,USD,956717,443228,89.46001,0.53010195,168.76 - 258.62,-0.3999939,-0.0015466472,168.76,258.62,1619640000,1634641140,1635163200,40.664566,6.35,9.54,PRE,0.9578907,254.55 - 258.62,255.77,0.0,258.04,13,10,us_market,0.85,,,258.62,168.76,236.17,214.26,956.72k,443.23k,52.86M,,51.71M,1.19%,106.41%,6.43M,10.99,12.30%,12.16%,5.68M,,,,,,0.00%,,,2:1,"Aug 12, 2008","Dec 30, 2020","Mar 30, 2021",11.49%,14.69%,8.56%,19.59%,2.94B,55.77,20.00%,819.9M,499.02M,337.76M,6.35,5.90%,944.18M,17.86,424.56M,21.95,2.01,36.59,537.2M,404.57M,Value,18,Healthcare,16070,"ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.",Dublin,353 1 291 2000,1609372800,Ireland,http://www.iconplc.com,86400,South County Business Park,353 1 247 6260,Diagnostics & Research,Leopardstown
t-1,ICLR,847519000.0,52860700,,,116403000,,101234000,88478000,225482000,119859000,119859000,,-3379000,,,,15169000,760229000,640370000,534747000,-3456000,,101234000,101234000,66460000.0,617104000.0,1585370000.0,1850236000.0,698495000.0,3435606000.0,4580000.0,1262895000.0,52149000.0,936257000.0,-34343000.0,50708000.0,840305000.0,1123943000.0,12705000.0,-34343000.0,258904000.0,2102978000.0,20299000.0,1729000.0,1207467000.0,348477000.0,101551000.0,4800000.0,-475000.0,231675000.0,-23504000.0,13339000.0,854000.0,132310000.0,5924000.0,195422000.0,24258000.0,-187776000.0,-46386000.0,4874000.0,-23029000.0,-45532000.0,979035000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,258.22,1630526403,2.449997,255.32,258.62,254.55,367713,43.963196,0.20518926,13649689600,27.067085,7.056734,15,America/New_York,EDT,-14400000,False,False,USD,2,ICON plc,NMS,9.13,28.282585,36.592,236.17372,22.04628,0.09334773,214.2568,0,finmb_397809,NasdaqGS,ICON Public Limited Company,USD,956717,443228,89.46001,0.53010195,168.76 - 258.62,-0.3999939,-0.0015466472,168.76,258.62,1619640000,1634641140,1635163200,40.664566,6.35,9.54,PRE,0.9578907,254.55 - 258.62,255.77,0.0,258.04,13,10,us_market,0.85,,,258.62,168.76,236.17,214.26,956.72k,443.23k,52.86M,,51.71M,1.19%,106.41%,6.43M,10.99,12.30%,12.16%,5.68M,,,,,,0.00%,,,2:1,"Aug 12, 2008","Dec 30, 2020","Mar 30, 2021",11.49%,14.69%,8.56%,19.59%,2.94B,55.77,20.00%,819.9M,499.02M,337.76M,6.35,5.90%,944.18M,17.86,424.56M,21.95,2.01,36.59,537.2M,404.57M,Value,18,Healthcare,16070,"ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.",Dublin,353 1 291 2000,1609372800,Ireland,http://www.iconplc.com,86400,South County Business Park,353 1 247 6260,Diagnostics & Research,Leopardstown
t-2,ICLR,727335000.0,52860700,,,105347000,,91641000,83117000,208319000,108401000,108401000,,-3239000,,,,13706000,701729000,593328000,493410000,-3054000,,91641000,91641000,69368000.0,610240000.0,1354182000.0,1711116000.0,840125000.0,3065298000.0,4579000.0,1161661000.0,48633000.0,914413000.0,-65364000.0,46926000.0,707995000.0,1243055000.0,14181000.0,-65364000.0,245728000.0,1771056000.0,17807000.0,1729000.0,1018382000.0,,28702000.0,,-3914000.0,53231000.0,-11343000.0,185000.0,10888000.0,115895000.0,4389000.0,111965000.0,23831000.0,-63408000.0,-4000.0,9872000.0,-6865000.0,10884000.0,528001000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,258.22,1630526403,2.449997,255.32,258.62,254.55,367713,43.963196,0.20518926,13649689600,27.067085,7.056734,15,America/New_York,EDT,-14400000,False,False,USD,2,ICON plc,NMS,9.13,28.282585,36.592,236.17372,22.04628,0.09334773,214.2568,0,finmb_397809,NasdaqGS,ICON Public Limited Company,USD,956717,443228,89.46001,0.53010195,168.76 - 258.62,-0.3999939,-0.0015466472,168.76,258.62,1619640000,1634641140,1635163200,40.664566,6.35,9.54,PRE,0.9578907,254.55 - 258.62,255.77,0.0,258.04,13,10,us_market,0.85,,,258.62,168.76,236.17,214.26,956.72k,443.23k,52.86M,,51.71M,1.19%,106.41%,6.43M,10.99,12.30%,12.16%,5.68M,,,,,,0.00%,,,2:1,"Aug 12, 2008","Dec 30, 2020","Mar 30, 2021",11.49%,14.69%,8.56%,19.59%,2.94B,55.77,20.00%,819.9M,499.02M,337.76M,6.35,5.90%,944.18M,17.86,424.56M,21.95,2.01,36.59,537.2M,404.57M,Value,18,Healthcare,16070,"ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.",Dublin,353 1 291 2000,1609372800,Ireland,http://www.iconplc.com,86400,South County Business Park,353 1 247 6260,Diagnostics & Research,Leopardstown
t-3,ICLR,604490000.0,52860700,,,54170000,,47760000,83499000,174395000,75038000,75038000,,-3220000,,,,6410000,620228000,545190000,445833000,-20868000,,47760000,47760000,72748000.0,592500000.0,1280237000.0,1578483000.0,764343000.0,2858720000.0,4569000.0,1070020000.0,46270000.0,901245000.0,-88606000.0,46184000.0,592100000.0,1169993000.0,15794000.0,-88606000.0,248819000.0,1578398000.0,11326000.0,1728000.0,946462000.0,,32722000.0,,-1087000.0,15091000.0,-10971000.0,-60041000.0,594000.0,109728000.0,2220000.0,117888000.0,22867000.0,91565000.0,-3000.0,11742000.0,-9850000.0,591000.0,408405000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,258.22,1630526403,2.449997,255.32,258.62,254.55,367713,43.963196,0.20518926,13649689600,27.067085,7.056734,15,America/New_York,EDT,-14400000,False,False,USD,2,ICON plc,NMS,9.13,28.282585,36.592,236.17372,22.04628,0.09334773,214.2568,0,finmb_397809,NasdaqGS,ICON Public Limited Company,USD,956717,443228,89.46001,0.53010195,168.76 - 258.62,-0.3999939,-0.0015466472,168.76,258.62,1619640000,1634641140,1635163200,40.664566,6.35,9.54,PRE,0.9578907,254.55 - 258.62,255.77,0.0,258.04,13,10,us_market,0.85,,,258.62,168.76,236.17,214.26,956.72k,443.23k,52.86M,,51.71M,1.19%,106.41%,6.43M,10.99,12.30%,12.16%,5.68M,,,,,,0.00%,,,2:1,"Aug 12, 2008","Dec 30, 2020","Mar 30, 2021",11.49%,14.69%,8.56%,19.59%,2.94B,55.77,20.00%,819.9M,499.02M,337.76M,6.35,5.90%,944.18M,17.86,424.56M,21.95,2.01,36.59,537.2M,404.57M,Value,18,Healthcare,16070,"ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.",Dublin,353 1 291 2000,1609372800,Ireland,http://www.iconplc.com,86400,South County Business Park,353 1 247 6260,Diagnostics & Research,Leopardstown
